A Novel Agent to Reduce the Requirement of Analgesics in Clinical Pain Management

N-methyl-d-aspartate (NMDA) receptor activation has been demonstrated to play an important role in the processing of spinal nociceptive information. Postsynaptic density protein-95 (PSD-95), a scaffolding protein, has been identified to attach NMDA receptors to internal signaling molecules at neuronal synapses. Previous studies have shown that the expression of spinal PSD-95 is critical for NMDA receptor-mediated pain hypersensitivity, and that spinal PSD-95 knockdown inhibits the development and maintenance of spinal nerve injury-induced pain behavioral responses. This invention provides therapeutic compositions and methods for reducing the amount of analgesics required for clinical pain management. These agents can be administered intraperitoneally, intrathecally or intravenously. Description (Set) Proposed Use (Set) Pain is the most common symptom responsible for individuals seeking health care. However, the relief of pain remains a largely unmet medical need with high prevalence of poorly controlled pain in chronic diseases. Many of the currently available pain therapies are either inadequate or causing uncomfortable to deleterious side effects. JHU researchers have developed novel agents that can markedly reduce the amount of analgesics needed to treat pain, thereby reducing the dose-dependent side effects of the analgesics. Patent (Set) PCT/US2008/60627

Inventor(s): Johns, Roger A.

Type of Offer: Licensing



« More Medical Patents

---